01—Abstract
Summary
Summary of the 8-K filed April 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. furnished a press release announcing leadership changes at its subsidiary Immunovant, Inc. and the expansion of IMVT-1402 into two new indications.
Eric Venker, M.D., Roivant's President and an Immunovant director, was appointed CEO of Immunovant, and Tiago Girao, formerly Telavant CFO, succeeded Renee Barnett as CFO. Pete Salzmann, M.D. retired as CEO and director. The company describes the changes as part of a broader strategic transition, in which development activities for batoclimab are concluding and activity on IMVT-1402 is ramping up, with increased Roivant operational involvement and strategic oversight.
On the pipeline, the filing states that an IND has been cleared for a potentially registrational program for IMVT-1402 in Sjögren's disease (SjD), its fifth indication, with the study expected to initiate in summer 2025. A proof-of-concept study in cutaneous lupus erythematosus (CLE), its sixth indication, has also been initiated. The company states that its current cash balance provides runway for the announced indications through a Graves' Disease readout expected in 2027.
Board and governance changes include George Migausky stepping down from the Immunovant board, and Robert Susman and Jacob Bauer joining, effective April 18, 2025. Roivant will also take over all Immunovant investor relations activity, and it hosted an investor call on April 21, 2025 at 8:00 a.m. EDT.
02—Key points
Key Highlights
- Eric Venker, M.D. (Roivant President and Immunovant director) appointed CEO of Immunovant; Tiago Girao, formerly Telavant CFO, appointed CFO, succeeding Renee Barnett.
- Pete Salzmann, M.D. retired as Immunovant CEO and director.
- IND cleared for a potentially registrational IMVT-1402 program in Sjögren's disease (SjD), its fifth indication; study expected to initiate in summer 2025.
- Proof-of-concept study of IMVT-1402 initiated in cutaneous lupus erythematosus (CLE), its sixth indication.
- Current cash balance stated to provide runway for announced indications through a Graves' Disease readout expected in 2027.
- Broader strategic transition: batoclimab development activities are beginning to conclude while IMVT-1402 development ramps up, with increased Roivant operational involvement and strategic oversight.
- Board changes effective April 18, 2025: George Migausky stepped down; Robert Susman and Jacob Bauer joined. Roivant will lead all Immunovant investor relations activity.
03—Questions
Frequently Asked Questions
Who is leading Immunovant after the leadership changes?
Eric Venker, M.D., Roivant's President and an Immunovant director, was appointed CEO and will continue to serve on Immunovant's board. Tiago Girao, formerly Telavant CFO, was appointed CFO, succeeding Renee Barnett.
What new indications is IMVT-1402 being developed for?
The filing announces an IND clearance for a potentially registrational program in Sjögren's disease (SjD), with the study expected to start in summer 2025. It also reports that a proof-of-concept study in cutaneous lupus erythematosus (CLE) has been initiated. The company describes these as its fifth and sixth indications.
How long is Immunovant's cash expected to last?
The company states its current cash balance provides runway for the announced indications through a Graves' Disease readout expected in 2027.
Why did the leadership change happen?
The company describes the change as part of a broader strategic transition, in which development activities for batoclimab are beginning to conclude and activity on IMVT-1402 is ramping up, with increased Roivant alignment and operational involvement.
Will investor communications change?
Yes. Roivant will lead all Immunovant investor relations activity, and investor and media queries are to be directed to the contacts listed in the press release.
04—Continue